Emerging Treatment Options for Familial Hypercholesterolemia

Cardiovascular Risk in Patients with Primary Hyperlipidemia and Familial Hypercholesterolemia (FH) - Program 2
1 AANP Contact Hours 1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s)
Launch Date:
June 11, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

General Cardiologists, Atherosclerosis Specialists, Interventional Cardiologists, Preventive Cardiologists, Diabetologists, Lipid and Metabolism Specialists

Relevant Terms:


Evan Stein, MD, PhD

Evan Stein, MD, PhD
Director Emeritus
Metabolic & Atherosclerosis Research Center
Cincinnati, OH

Evan A. Stein, MD, PhD is the Director Emeritus of the Metabolic & Atherosclerosis Research Center in Cincinnati, Ohio. He received his medical degree and doctorate from the University of Witwatersrand Medical School in Johannesburg, South Africa.  He has had several appointments to the National Institutes of Health (NIH) since 1986, including serving with the National Cholesterol Education Program. He served on the Data and Safety Advisory Board of the National Heart, Lung, and Blood Institute Program on Genetics in Hypertension from 1999-2003. He was appointed to the Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Advisory Panel and served from 2006 through 2010. Dr. Stein has authored more than 300 publications in the area of clinical, therapeutic and laboratory aspects of lipid metabolism especially familial hypercholesterolemia.

Michael H. Davidson, MD

Michael H. Davidson, MD
Clinical Professor of Medicine
Director, Preventive Cardiology
The University of Chicago
Pritzker School Of Medicine
Chicago, IL

Michael Davidson, MD is a Clinical Professor of Medicine and the Director of the Preventive Cardiology Program at the University Of Chicago Pritzker School Of Medicine in Illinois. Dr. Davidson has been named one of "The Best Doctors in America" by Best Doctors Inc. He is a past president of the National Lipid Association. Dr. Davidson has coordinated more than 1,000 clinical trials in preventive cardiology, authored more than 250 articles in leading medical journals, and lectured extensively on lipid disorders, nutrition and atherosclerosis.
1. Review the underlying genetic mutations and the role of genetic screening for heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) as it relates to diagnosis and treatment of familial hypercholesterolemia and in response to statins, ezetimibe and proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody treatment
2. Discuss the emerging evidence on genetic mutations and their potential therapeutic significance in the development of novel low-density lipoprotein cholesterol (LDL-C) targets
3. Identify the relationship of LDL-C reduction and cardiovascular disease (CVD) risk reduction including the risk in HeFH and HoFH
4. Discuss the clinical presentation and implications of HeFH and the use of optimal LDL-C target goals for these patients based on current consensus recommendations 

Disclosure of Conflicts Of Interest Policy​
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Faculty Disclosures
Evan Stein, MD, PhD discloses the following relevant financial relationships:
Consultant - Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Catabasis Pharmaceuticals, Inc.; CymaBay Therapeutics; Gemphire Therapeutics Inc.; Genentech, Inc., a member of the Roche Group; Regeneron Pharmaceuticals, Inc.  
Clinical Investigator - Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc., a member of the Roche Group; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. Inc.
Michael H. Davidson, MD discloses the following relevant financial relationships:
Consultant - Amgen, Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. Inc.
Margaret V. Clark, MS, RN, RRT – NPS, Medical Writer
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
Accreditor Disclosures
Dorothy Caputo, MA, BSN, RN- Lead Nurse Planner
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
Bernadette Marie Makar, MSN, NP-C, APRN-C- Nurse Planner
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use​
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
This activity is supported by an educational grant from Amgen Inc. and sanofi-aventis U.S. Inc.
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 1.0 contact hour.
Nurse Practitioners
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number: 030803.
This program is accredited for 1.0 contact hour, which includes 0.75 hours of pharmacology. 
Program ID #21510.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. You must participate in the entire activity to receive credit. If you have questions about this CME/CE activity, please contact AKH Inc. at jgoldman@akhcme.com.
Privacy Policy
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.